SR-9009

SR-9009, also known by its research code Stenabolic, is a synthetic compound that has been extensively studied for its role as a Rev-ErbA alpha (Rev-ErbAα) agonist. Rev-ErbAα is a nuclear receptor involved in regulating circadian rhythms and metabolism. While not a Selective Androgen Receptor Modulator (SARM), SR-9009 is often discussed in contexts similar to SARMs due to its reported effects on body composition and endurance in preclinical studies. It was developed at The Scripps Research Institute and has primarily been investigated for its potential to influence energy balance, glucose metabolism, and lipid profiles. Preclinical research, mainly conducted in mouse models, indicates that SR-9009 can impact various metabolic processes. These include increasing mitochondrial content and activity in skeletal muscle, which may contribute to improved exercise capacity, and influencing fat and glucose metabolism. The compound is not approved for human use by regulatory bodies like the FDA, and its status is strictly limited to research. Information regarding its efficacy and safety in humans is derived from early-stage research and anecdotal reports, rather than robust clinical trials. (Source: PubChem, DrugBank)